Core Viewpoint - The company, Jibeier, has recently received a patent certificate from the National Intellectual Property Administration for an invention related to "a paclitaxel derivative and its preparation method and application" [2] Group 1 - The patent signifies a potential advancement in the pharmaceutical sector, particularly in cancer treatment, as paclitaxel is a well-known chemotherapeutic agent [2] - The issuance of this patent may enhance the company's competitive position in the market by protecting its intellectual property and potentially leading to new product developments [2] - This development could attract investor interest, as patents often indicate future revenue streams and innovation capabilities [2]

Core Viewpoint - The company has recently received a patent certificate from the National Intellectual Property Administration for an invention related to a paclitaxel derivative and its preparation method, which enhances the quality control and pharmacological activity of paclitaxel-based anticancer compounds [1] Group 1: Patent Details - The patent is titled "A Paclitaxel Derivative and Its Preparation Method, Application" with patent number ZL 2023 1 1469030.2 [1] - The invention pertains to the field of medicinal chemistry, specifically focusing on a paclitaxel derivative that can be used for detecting impurities in paclitaxel-based anticancer compounds [1] Group 2: Benefits of the Invention - The compound provided by the invention can significantly reduce the toxicity or side effects of paclitaxel-based anticancer drugs and improve their long-term stability [1] - Controlling the content of the paclitaxel derivative has notable benefits for enhancing the pharmacological activity of the drug [1] Group 3: Strategic Implications - The acquisition of this patent reflects and extends the company's core technology [1] - While the patent will not have a significant immediate impact on the company's operations, it is beneficial for enhancing the company's intellectual property protection system and promoting technological innovation [1] - This development is expected to strengthen the company's core competitiveness through the utilization of proprietary technology [1]

Core Viewpoint - The company has received a patent for a novel taxane derivative and its preparation method, which will enhance its intellectual property protection and competitiveness in the market [1] Group 1: Patent Details - The patent is titled "A Taxane Derivative and Its Preparation Method, Application" with patent number ZL202311469030.2 [1] - The application date for the patent was November 7, 2023, and the authorization announcement date is December 16, 2025 [1] - The patent is valid for a period of 20 years [1] Group 2: Implications of the Patent - The invention can be utilized for impurity detection in taxane-based anticancer compounds, aiding in quality control [1] - While the patent will not have a significant impact on the company's recent operations, it contributes to the enhancement of the intellectual property protection system [1] - The patent is expected to improve the company's competitive edge in the industry [1]